Biotech Drug Report Generated Oct 25, 2026

VK2809

VKTX·Viking Therapeutics, Inc

BEARISH

Drug Impact Rating2/10

Trial Phase: Phase 2 (completed/on hold)
Time to Market: Unknown; the program is in legal limbo due to a license dispute.
Why 2/10: VK2809 has no scheduled near-term catalyst within the next ~12 months. The drug is not Viking's lead program (VK2735 obesity candidate is), a license termination dispute with Ligand is ongoing, and data from recent financings explicitly earmark proceeds for VK2735 and VK3019, not VK2809. As a deprioritized, non-catalyst asset, impactScore is low regardless of VK2809's potential market.

Actionable Insight ▼ BEARISH

VK2809 is not a near-term catalyst for VKTX. Investors should monitor the Ligand license dispute for resolution, but the real value driver for the stock is the VK2735 obesity program. The $534M capital raise in September 2026 was explicitly earmarked for VK2735 and VK3019, not VK2809.

Price Chart

Loading chart...

Executive Summary

VK2809 is a thyroid hormone receptor beta (TR-β) agonist being developed for NASH/MASH and hypercholesterolemia by Viking Therapeutics (VKTX). The drug was originally in-licensed from Ligand Pharmaceuticals. In April 2026, Ligand terminated the TR-Beta Program license, alleging Viking breached its obligation to use commercially reasonable efforts to develop and commercialize the program. Viking disputes the termination. The drug appears to have been deprioritized by Viking, which is now focused on its lead obesity asset VK2735 (currently in Phase 3) and its early-stage amylin agonist VK3019. With no active clinical trials visible in the ingested data and a license dispute creating legal overhang, VK2809 has uncertain prospects and is a minor part of the VKTX story.

How It Works

VK2809 is a thyroid hormone receptor beta (TR-β) agonist. It is designed to selectively activate the TR-β receptor in the liver, which plays a key role in regulating fat metabolism. By activating this receptor, the drug aims to reduce liver fat, inflammation, and fibrosis in patients with non-alcoholic steatohepatitis (NASH, also called MASH) and potentially lower cholesterol.

Trial Status

VK2809 previously completed Phase 2 clinical trials for NASH and hypercholesterolemia. However, the program has been disrupted by a license termination dispute with Ligand Pharmaceuticals (April 2026). Viking's current pipeline focus has shifted entirely to VK2735 (GLP-1/GIP dual agonist for obesity, now in Phase 3) and VK3019 (amylin agonist). No active VK2809 clinical trials appear in the ingested data.

The Two-Sided Case

▲ Bull Case2

Thyroid hormone receptor beta agonists have shown promise in reducing liver fat in NASH patients, a large unmet medical need with few approved treatments.

If the Ligand license dispute is resolved in Viking's favor, the program could be revived and potentially partnered or advanced.

▼ Bear Case5

Ligand terminated the TR-Beta Program license in April 2026, alleging Viking materially breached its development obligations — legal uncertainty clouds the program's future.

Viking has clearly deprioritized VK2809, focusing capital on VK2735 (obesity Phase 3) and VK3019 (amylin); the $534M capital raise in Sept 2026 was designated for those programs, not VK2809.

VK2809 faces competition from Madrigal's Rezdiffra (resmetirom), the first FDA-approved TR-β agonist for NASH, which is already on the market.

No active clinical trials are visible for VK2809 in the ingested data, suggesting the program is paused or on hold.

Short interest of ~20.6% of outstanding shares and the stock trading near its 52-week low reflect broader bearish sentiment on VKTX.

Upcoming Catalysts

Resolution of the Ligand license termination dispute
Potential re-evaluation of pipeline priority by Viking management

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Viking Therapeutics, Inc PRESS-RELEASE VKTX ·Originating report

Sources · 3

Hover a chip for the title

1 sec.gov 2 sec.gov 3 sec.gov